BOSTON, June 20, 2011 /PRNewswire/ -- Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that its Clinical Trial Management System is available as an on-demand, software-as-a-service (SaaS) application. The SaaS-based CTMS, which is hosted, maintained and supported entirely by Perceptive Informatics, enables sponsors to plan, administer and track clinical trial activities in a cost effective and efficient manner.
According to Nicholas Richards, Vice President, Product Management, Perceptive Informatics, "Biopharmaceutical companies continue to seek ways to decrease development costs by improving overall efficiency. SaaS-enabled technologies are experiencing tremendous acceptance because they can be rapidly implemented, eliminate up-front capital investment, and decrease associated maintenance. The CTMS solution in a SaaS delivery model is designed for organizations that can benefit from improving clinical trial productivity and reducing operational and IT costs."
The Perceptive Informatics® SaaS-Based CTMS solution allows sponsors to save time in study start-up due to a rapid, flexible, scalable and secure deployment approach supported by Perceptive's eClinical platform. A subscription option provides users with the benefits of an on-premise solution without the need for up-front investments or additional internal resources.
The CTMS solution is part of the Perceptive Informatics eClinical Suite, which provides convergence among systems for real-time data interchange and enables diverse applications to work synergistically. Organizations can maximize the capabilities of the CTMS solution due to its interoperability with the Perceptive Informatics RTSM (Randomization and Trial Supply Management) and EDC solutions, which allows users to seamlessly share clinical trial data without having to duplicate activities.
For more information about the Perceptive Informatics CTMS solution visit: http://www.perceptive.com/CTMS. For more information about the Perceptive Informatics eClinical Suite visit: http://www.perceptive.com/Solutions/eClinical-Suite.
About Perceptive InformaticsPerceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit www.perceptive.com.
About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,350 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $15 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations
Gene Carozza/Kim BakerPAREXEL International
PAN CommunicationsTel: +781-434-4409
Tel: +978-474-1900Email: Jennifer.Baird@PAREXEL.com
|SOURCE PAREXEL International Corporation|
Copyright©2010 PR Newswire.
All rights reserved